Adlai Nortye Ltd. ANL

Updated: 10 Aug 2026

NASDAQ | Biotech | Biotechnology / Oncology

No signal published yet

We already track Adlai Nortye and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Adlai Nortye free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology / Oncology
We're already tracking Adlai Nortye Ltd. — here are the latest events we've registered

Recent News

  • On August 3, 2026, Adlai Nortye announced that it submitted a clinical trial notification and received ethics approval in Australia to initiate a Phase 1 clinical trial for AN4035.

What Firelda Watch includes for Adlai Nortye Ltd.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Adlai Nortye Ltd. will be delivered in the same format.

Want to follow Adlai Nortye Ltd.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Adlai Nortye free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Adlai Nortye Ltd. ANL
Adlai Nortye — follow and we'll monitor it
Follow Adlai Nortye free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.